ACCURAY INC (ARAY)

ACCURAY manufactures and sells precision radiation therapy systems that hospitals and cancer centers use to treat tumors with pinpoint accuracy. The company is headquartered in Sunnyvale, California, and trades on NASDAQ under the ticker ARAY.

The core of ACCURAY’s business is its CyberKnife platform, a frameless robotic radiosurgery system that delivers tightly focused radiation beams to cancerous tissue. Unlike traditional linear accelerators, CyberKnife does not require head frames or rigid positioning—patients can be treated more comfortably while the robotic arm adjusts in real time as it “sees” the tumor’s exact position through integrated imaging. This reduces planning complexity and often shortens treatment courses, which appeals to hospitals competing for patient volumes. The company also sells TomoTherapy, a system that merges radiation delivery with computed tomography scanning, offering an integrated workflow for treatment planning and execution.

Revenue flows from two channels. Equipment sales form the primary stream—each system costs hundreds of thousands to millions of dollars, and hospitals must budget capital carefully for such purchases. The second and increasingly important stream comes from recurring fees: maintenance contracts, software licenses, service agreements, and ongoing support. A cancer center that owns a CyberKnife or TomoTherapy system becomes a long-term customer, paying annually for the privilege of keeping it running and updated.

Precision in oncology is not a luxury—it is a clinical and economic necessity.

Hospitals today operate under tight reimbursement constraints and demand equipment that justifies its cost through proven outcomes and operational efficiency. ACCURAY’s market sits at the intersection of technology sophistication and medical necessity. Radiation oncology is foundational to cancer care; survival rates and quality of life for patients depend on accurate targeting and minimal collateral damage to healthy tissue. This clinical imperative creates demand that is less vulnerable to economic cycles than many medical device markets.

Competition is substantial. Traditional manufacturers like Siemens and Varian (now part of Siemens) dominate with linear accelerator platforms used in nearly every cancer center. Proton therapy companies offer an alternative for certain tumor types, though at higher cost. Smaller innovators push into particle therapy and other modalities. ACCURAY’s differentiation rests on CyberKnife’s ease of use, real-time tracking, and clinical evidence showing comparable or superior outcomes with shorter treatment times. Whether that edge translates to market share gains depends on hospital adoption patterns, reimbursement policies, clinical publications, and the company’s ability to reduce system costs as competitors innovate.

The investment thesis hinges on several moving parts: the pace of cancer treatment center expansion and equipment replacement cycles, the strength of hospital capital budgets, the durability of ACCURAY’s clinical advantages, and whether larger competitors can replicate or surpass its technology. Oncology equipment markets are mature but growing in absolute terms as cancer incidence rises globally. Success requires sustained clinical evidence, competitive pricing, and the discipline to manage costs while funding R&D.